The Survey of Treatment and Metabolic Status of Type 1 Diabetes Mellitus (T1DM).

Condition(s) studied

Investigational drug(s) / intervention(s)

Continuous Glucose Monitoring System (GX-01S): Patients with Type 1 Diabetes Mellitus (T1DM) will receive Continuous Glucose Monitoring System (GX-01S) for seven days.

Study summary

This study is a multicenter cross-sectional research project, planning to enroll 1000 patients with Type 1 Diabetes Mellitus (T1DM). By reviewing clinical data, physical examinations, questionnaires, continuous glucose monitoring, and subcutaneous fat ultrasound, we aim to understand the current status of treatment and metabolism in Chinese T1DM patients and analyze the potential factors that may affect their blood sugar control and metabolic indicators. A cost-effectiveness analysis will be conducted on Chinese T1DM patients using continuous glucose monitoring systems to identify the groups that benefit most from these systems.

Eligibility

Primary outcome measure(s)

• Current status of blood sugar control in Chinese patients with type 1 diabetes — 3 years
  Using continuous glucose monitoring systems to understand the current status of blood sugar control in Chinese patients with type 1 diabetes; analyzing the possible factors that may affect the glycometabolic indicators of Chinese patients with type 1 diabetes.
• Understand the current status of the use of continuous glucose monitoring in China for type 1 diabetes — 3 years
  Understand the current status of the use of continuous glucose monitoring in China for type 1 diabetes, and analyze its impact on blood sugar control, acute and chronic complications, and quality of life for patients with type 1 diabetes
• Potential beneficiary groups of continuous glucose monitoring — 3 years
  Through cost-effectiveness analysis, identify the potential beneficiary groups of continuous glucose monitoring to provide objective evidence for the demand for this technology by healthcare professionals and diabetes patients; provide effective information for the formulation of medical insurance reimbursement policies for continuous glucose monitoring.

Trial sites (101)

+ 61 more sites — see the full list on the official registry below.

More Nanjing First Hospital, Nanjing Medical University trials in China

Other trials for the same condition